drugset / Trial / NCT07583030
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
Phase 0
Not yet recruiting
44 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory autoimmune diseases.
Timeline
- Start
- 2026-04-20
- Primary completion
- 2028-09-20
- Completion
- 2041-09-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LVIVO-TaVec400 | Cell therapy | — | Intravenous |